patient view
This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.
drug
AMBRISENTAN
Marketedupdated 2mo agoby Sigmapharm Laboratories LLC
Approvedcommunity read0 votes
all catalysts(17)
approval · 17
Mar 28, 2019
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Apr 10, 2019
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Nov 29, 2019
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Dec 22, 2020
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Dec 22, 2020
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Jun 8, 2021
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Jun 8, 2021
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
May 19, 2022
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Aug 19, 2024
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Aug 19, 2024
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Aug 19, 2024
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Apr 4, 2025
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Apr 4, 2025
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Apr 4, 2025
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Sep 19, 2025
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Feb 17, 2026
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that